Mitochondrial metabolism inhibitors for cancer therapy

Pharmaceutical Research

Volumn 28, Issue 11, 2011, Pages 2731-2744

  Ramsay, Emma E ^a   Hogg, Philip J ^a   Dilda, Pierre J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Adenine nucleotide translocase; Cancer; Hexokinase; Metabolism; Mitochondria

Indexed keywords

4 [N (S CYSTEINYLACETYL)AMINO]PHENYLARSONOUS ACID; 4 [N (S CYSTEINYLGLYCYLCELATYL)AMINO]PHENYLARSONOUS ACID; 4 [N (S GLUATATHIONYLACETYL)AMINO]PHENYLARSONOUS ACID; 4 [N (S PENICILLAMINYLACETYL)AMINO]PHENYLARSONOUS ACID; 6 DIAZO 5 OXONORLEUCINE; ALPHA TOCOPHEROL DERIVATIVE; AMINOOXYACETIC ACID; ANTINEOPLASTIC AGENT; AZASERINE; AZD 7545; BENZYL ISOTHIOCYANATE; BEVIRIMAT; BIFONAZOLE; BROMOPYRUVIC ACID; BULLATACIN; CLOTRIMAZOLE; DEOXYGLUCOSE; GLUTAMINOLYSIS INHIBITOR; GLYCOLYSIS INHIBITOR; HONOKIOL; JASMONIC ACID; LONIDAMINE; MANNOHEPTULOSE; MITOCHONDRIAL ATP TRANSPORT INHIBITOR; OXIDATIVE PHOSPHORYLATION INHIBITOR; RESVERATROL; ROTENONE; SMALL MOLECULE MITOCHONDRIAL METABOLISM INHIBITOR; THIOGLUCOSE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SYNTHESIS; BONE MARROW SUPPRESSION; BRAIN TUMOR; BREAST CANCER; CANCER INHIBITION; CANCER THERAPY; CELL METABOLISM; COLORECTAL CANCER; DRUG MECHANISM; DRUG SCREENING; DYSPLASTIC NEVUS; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLYCOLYSIS; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LIVER TUMOR; LUNG CANCER; LUNG TUMOR; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; NEUROBLASTOMA; NEUROTOXICITY; NONHUMAN; OVARY CANCER; OVARY TUMOR; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE ADENOMA; PROSTATE CANCER; REVIEW; SKIN CANCER; SOLID TUMOR;

ADENOSINE TRIPHOSPHATASES; CELL GROWTH PROCESSES; GLYCOLYSIS; HEXOKINASE; HUMANS; MITOCHONDRIA; MITOCHONDRIAL ADP, ATP TRANSLOCASES; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84856227857     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0584-5     Document Type: Review

References (199)

1. Warburg O. On the origin of cancer cells. Science. 1956;123 (3191):309-14.
2. Moreno-Sánchez R, Rodríguez-Enríquez S, Saavedra E, Marín- Hernández A, Gallardo-Pérez JC. The bioenergetics of cancer: is glycolysis the main ATP supplier in all tumor cells? Biofactors. 2009;35(2):209-25.
3. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85-95.
4. Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, Saavedra E. Energy metabolism in tumor cells. FEBS J. 2007;274(6):1393-418. (Pubitemid 46333738)
5. Solaini G, Sgarbi G, Baracca A. Oxidative phosphorylation in cancer cells. Biochim Biophys Acta Bioenerg. 2011;1807(6):534-42.
6. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-33.
7. Pedersen PL. Warburg, me and Hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr. 2007;39(3):211-22. (Pubitemid 47619382)
8. Matés JM, Segura JA, Campos-Sandoval JA, Lobo C, Alonso L, Alonso FJ, et al. Glutamine homeostasis and mitochondrial dynamics. Int J Biochem Cell Biol. 2009;41(10):2051-61.
9. Medina MA, Sánchez-Jiménez F, Márquez J, Rodríguez Quesada A, Núñez I. Relevance of glutamine metabolism to tumor cell growth. Mol Cell Biochem. 1992;113(1):1-15.
10. Medina MA, De Castro IN. Glutaminolysis and glycolysis interactions in proliferant cells. Int J Biochem. 1990;22 (7):681-3. (Pubitemid 20374318)
11. Dasu A, Toma-Dasu I, Karlsson M. Theoretical simulation of tumour oxygenation and results from acute and chronic hypoxia. Phys Med Biol. 2003;48(17):2829-42. (Pubitemid 37121463)
12. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8(9):705-13.
13. Yeung S, Pan J, Lee MH. Roles of p53, Myc and HIF-1 in regulating glycolysis-the seventh hallmark of cancer. Cell Mol Life Sci. 2008;65(24):3981-99.
14. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem. 2000;275(29):21797-800. (Pubitemid 30621745)
15. Shim H, Dolde C, Lewis BC, Wu C-S, Dang G, Jungmann RA, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA. 1997;94 (13):6658-63. (Pubitemid 27281920)
16. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA. 2008 Dec 2;105(48):18782-7.
17. Kim J-W, Gao P, Liu Y-C, Semenza GL, Dang CV. Hypoxiainducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol. 2007;27(21):7381-93. (Pubitemid 350033646)
18. Cuezva JM, Ortega ÁD, Willers I, Sánchez-Cenizo L, Aldea M, Sánchez-Aragó M. The tumor suppressor function of mitochondria: Translation into the clinics. Biochimica et Biophysica Acta-Molecular Basis of Disease. 2009;1792(12):1145-58.
19. Mathupala SP, Ko YH, Pedersen PL. The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta. 2010:1225-30.
20. Wasserman DH, Kang L, Ayala JE, Fueger PT, Lee-Young RS. The physiological regulation of glucose flux into muscle in vivo. J Exp Biol. 2011;214(2):254-62.
21. Mathupala SP, Ko YH, Pedersen PL. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg effect" and a pivotal target for effective therapy. Semin Cancer Biol. 2009;19(1):17-24.
22. Pastorino JG, Hoek JB. Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr Med Chem. 2003;10 (16):1535-51. (Pubitemid 36896555)
23. Goel A, Mathupala SP, Pedersen PL. Glucose metabolism in cancer: evidence that demethylation events play a role in activating type II hexokinase gene expression. J Biol Chem. 2003;278(17):15333-40. (Pubitemid 36799872)
24. Rempel A, Mathupala SP, Griffin CA, Hawkins AL, Pedersen PL. Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase. Cancer Res. 1996;56(11):2468-71. (Pubitemid 26170674)
25. Smith TAD. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci. 2000;57(2):170-8. (Pubitemid 30417071)
26. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem. 2001;276(46):43407-12.
27. Mathupala SP, Heese C, Pedersen PL. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem. 1997;272(36):22776-80. (Pubitemid 27386097)
28. Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 2006;25 (34):4777-86. (Pubitemid 44187625)
29. Rempel A, Bannasch P, Mayer D. Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages. Biochim Biophys Acta Gene Struct Expr. 1994;1219(3):660-8. (Pubitemid 24353384)
30. Nakashima RA, Mangan PS, Colombini M, Pedersen PL. Hexokinase receptor complex in hepatoma mitochondria: evidence from N, N-dicyclohexylcarbodiimide- labeling studies for the involvement of the pore-forming protein VDAC. Biochemistry. 1986;25(5):1015-21. (Pubitemid 16099500)
31. Arora KK, Pedersen PL. Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. J Biol Chem. 1988;263(33):17422-8. (Pubitemid 19029327)
32. Bustamante E, Pedersen PL. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci USA. 1977;74(9):3735-9. (Pubitemid 8189957)
33. Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem. 2002;277(9):7610-8. (Pubitemid 34953160)
34. Arzoine L, Zilberberg N, Ben-Romano R, Shoshan-Barmatz V. Voltage-dependent anion channel 1-based peptides interact with hexokinase to prevent its anti-apoptotic activity. J Biol Chem. 2009;284(6):3946-55.
35. Pastorino JG, Hoek JB. Regulation of hexokinase binding to VDAC. J Bioenerg Biomembr. 2008;40(3):171-82.
36. Poleti MD, Tesch AC, Crepaldi CR, Souza GHMF, Eberlin MN, De Cerqueira César M. Relationship between expression of voltage-dependent anion channel (VDAC) isoforms and type of hexokinase binding sites on brain mitochondria. J Mol Neurosci. 2010;41(1):48-54.
37. Golestani A, Nemat-Gorgani M. Hexokinase 'binding sites' of normal and tumoral human brain mitochondria. Mol Cell Biochem. 2000;215(1-2):115-21. (Pubitemid 32094949)
38. de Cerqueira Cesar M, Wilson JE. Functional characteristics of hexokinase bound to the Type A and Type B sites of bovine brain mitochondria. Arch Biochem Biophys. 2002;397 (1):106-12. (Pubitemid 34848255)
39. Vyssokikh MY, Zorova L, Zorov D, Heimlich G, Jürgensmeier JM, Brdiczka D. Bax releases cytochrome c preferentially from a complex between porin and adenine nucleotide translocator. Hexokinase activity suppresses this effect. Mol Biol Rep. 2002;29 (1-2):93-6. (Pubitemid 35021867)
40. Vyssokikh M, Zorova L, Zorov D, Heimlich G, Jürgensmeier J, Schreiner D, et al. The intra-mitochondrial cytochrome c distribution varies correlated to the formation of a complex between VDAC and the adenine nucleotide translocase: this affects Bax-dependent cytochrome c release. Biochim Biophys Acta Mol Cell Res. 2004;1644(1):27-36. (Pubitemid 38117039)
41. Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V. In self-defence: hexokinase promotes voltagedependent anion channel closure and prevents mitochondriamediated apoptotic cell death. Biochem J. 2004;377(2):347-55. (Pubitemid 38142190)
42. Campbell AM, Chan SHP. The voltage dependent anion channel affects mitochondrial cholesterol distribution and function. Arch Biochem Biophys. 2007;466(2):203-10. (Pubitemid 47451339)
43. Chevrollier A, Leiseau D, Stepien G. What is the specific role of ANT2 in cancer cells? Medicine/Sciences. 2005;21(2):156-61. (Pubitemid 40269055)
44. Chevrollier A, Loiseau D, Chabi B, Renier G, Douay O, Malthiery Y, et al. ANT2 isoform required for cancer cell glycolysis. J Bioenerg Biomembr. 2005;37(5):307-16. (Pubitemid 41778770)
45. Perevoshchikova IV, Zorov SD, Kotova EA, Zorov DB, Antonenko YN. Hexokinase inhibits flux of fluorescently labeled ATP through mitochondrial outer membrane porin. FEBS Lett. 2010;584(11):2397-402.
46. Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th ed. New York Basingstoke: W. H. Freeman and Co.; Palgrave distributor; 2001.
47. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumorassociated stroma. Neoplasia. 2005;7(1):1-6. (Pubitemid 40209465)
48. Koukourakis MI, Giatromanolaki A, Bougioukas G, Sivridis E. Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. Cancer Biol Ther. 2007;6(9):1476-9. (Pubitemid 351590361)
49. McFate T, Mohyeldin A, Lu H, Thakar J, Henriques J, Halim ND, et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem. 2008;283(33):22700-8.
50. Wigfield SM, Winter SC, Giatromanolaki A, Taylor J, Koukourakis ML, Harris AL. PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer. Br J Cancer. 2008;98(12):1975-84. (Pubitemid 351821556)
51. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452(7184):230-3. (Pubitemid 351380249)
52. Pathania D, Millard M, Neamati N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Deliv Rev. 2009;61(14):1250-75.
53. Hao H-X, Khalimonchuk O, Schraders M, Dephoure N, Bayley J-P, Kunst H, et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science. 2009;325(5944):1139-42.
54. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287(5454):848-51. (Pubitemid 30084326)
55. Bayley J-P, Devilee P. Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree? Curr Opin Genet Dev. 2010;20(3):324-9.
56. Rutter J, Winge DR, Schiffman JD. Succinate dehydrogenase-assembly, regulation and role in human disease. Mitochondrion. 2010;10(4):393-401.
57. Yang Y, Valera VA, Padilla-Nash HM, Sourbier C, Vocke CD, Vira MA, et al. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet. 2010;196(1):45-55.
58. Furuta E, Okuda H, Kobayashi A, Watabe K. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta Rev Canc. 2010;1805 (2):141-52.
59. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11-20.
60. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-73.
61. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-44.
62. Keenan J, Liang Y, Clynes M. Two-deoxyglucose as an antimetabolite in human carcinoma cell line RPMI-2650 and drugresistant variants. Anticancer Res. 2004;24(2A):433-40. (Pubitemid 38623117)
63. Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K, et al. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate. 2010;70(13):1388-94.
64. Board M, Colquhoun A, Newsholme EA. High Km glucosephosphorylating (glucokinase) activities in a range of tumor cell lines and inhibition of rates of tumor growth by the specific enzyme inhibitor mannoheptulose. Cancer Res. 1995;55 (15):3278-85.
65. Penso J, Beitner R. Clotrimazole and bifonazole detach hexokinase from mitochondria of melanoma cells. Eur J Pharmacol. 1998;342(1):113-7. (Pubitemid 28131352)
66. Khalid MH, Tokunaga Y, Caputy AJ, Walters E. Inhibition of tumor growth and prolonged survival of rats with intracranial gliomas following administration of clotrimazole. J Neurosurg. 2005;103(1):79-86. (Pubitemid 43193938)
67. Liu H, Li Y, Raisch KP. Clotrimazole induces a late G1 cell cycle arrest and sensitizes glioblastoma cells to radiation in vitro. Anticancer Drugs. 2010;21(9):841-9.
68. Hegemann L, Toso SM, Lahijani KI, Webster GF, Uitto J. Direct interaction of antifungal azole-derivatives with calmodulin: a possible mechanism for their therapeutic activity. J Invest Dermatol. 1993;100(3):343-6. (Pubitemid 23083196)
69. Papandreou I, Goliasova T, Denko NC. Anticancer drugs that target metabolism: is dichloroacetate the new paradigm? Int J Cancer. 2011;128(5):1001-8.
70. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11(1):37-51. (Pubitemid 46054520)
71. Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, et al. Dichloroacetate (DCA) sensitizes both wild-type and over expressing bcl-2 prostate cancer cells in vitro to radiation. Prostate. 2008;68(11):1223-31.
72. Stockwin LH, Yu SX, Borgel S, Hancock C, Wolfe TL, Phillips LR, et al. Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC. Int J Cancer. 2010;127 (11):2510-9.
73. Sun R, Fadia M, Dahlstrom J, Parish C, Board P, Blackburn A. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat. 2010;120(1):253-60.
74. Wong JYY, Huggins GS, Debidda M, Munshi NC, De Vivo I. Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol. 2008;109(3):394-402.
75. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Translat Med. 2010;2(31).
76. Pearson H. Cancer patients opt for unapproved drug. Nature. 2007;446(7135):474-5. (Pubitemid 46514699)
77. Morrell JA, Orme J, Butlin RJ, Roche TE, Mayers RM, Kilgour E. AZD7545 is a selective inhibitor of pyruvate dehydrogenase kinase 2. Biochem Soc Trans. 2003;31(6):1168-70. (Pubitemid 38030932)
78. Kato M, Li J, Chuang JL, Chuang DT. Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. Structure. 2007;15(8):992-1004. (Pubitemid 47212754)
79. Mayers RM, Butlin RJ, Kilgour E, Leighton B, Martin D, Myatt J, et al. AZD7545, a novel inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2), activates pyruvate dehydrogenase in vivo and improves blood glucose control in obese (fa/fa) Zucker rats. Biochem Soc Trans. 2003;31(6):1165-7. (Pubitemid 38030931)
80. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 2010;9(6):447-64.
81. Ishii N. Role of oxidative stress from mitochondria on aging and cancer. Cornea. 2007;26 Suppl 1:S3-9. (Pubitemid 47442754)
82. Fukuda R, Zhang H, Kim J-W, Shimoda L, Dang CV, Semenza Gregg L. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell. 2007;129(1):111-22. (Pubitemid 46507584)
83. Boitier E, Merad-Boudia M, Guguen-Guillouzo C, Defer N, Ceballos-Picot I, Leroux JP, et al. Impairment of the mitochondrial respiratory chain activity in diethylnitrosamine-induced rat hepatomas: possible involvement of oxygen free radicals. Cancer Res. 1995;55(14):3028-35.
84. Simonnet H, Demont J, Pfeiffer K, Guenaneche L, Bouvier R, Brandt U, et al. Mitochondrial complex I is deficient in renal oncocytomas. Carcinogenesis. 2003;24(9):1461-6. (Pubitemid 37160836)
85. Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, et al. Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res. 2006;66 (12):6087-96.
86. Simonnet H, Alazard N, Pfeiffer K, Gallou C, Béroud C, Demont J, et al. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis. 2002;23(5):759-68. (Pubitemid 34567514)
87. Cuezva JM, Krajewska M, De Heredia ML, Krajewski S, Santamaría G, Kim H, et al. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res. 2002;62 (22):6674-81. (Pubitemid 35364137)
88. Cuezva JM, Chen G, Alonso AM, Isidoro A, Misek DE, Hanash SM, et al. The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis. 2004;25(7):1157-63. (Pubitemid 38968043)
89. Deng Y, Huang H, Lin J. Rotenone induces apoptosis in MCF-7 human breast cancer cell-mediated ROS through JNK and p38 signaling. Mol Carcinog. 2010;49(2):141-51.
90. Wolvetang EJ, Johnson KL, Krauer K, Ralph SJ, Linnane AW. Mitochondrial respiratory chain inhibitors induce apoptosis. FEBS Lett. 1994;339(1-2):40-4. (Pubitemid 24086647)
91. Chung WG, Miranda CL, Maier CS. Epigallocatechin gallate (EGCG) potentiates the cytotoxicity of rotenone in neuroblastoma SH-SY5Y cells. Brain Res. 2007;1176(1):133-42. (Pubitemid 47553116)
92. Liaw C-C, Wu T-Y, Chang F-R, Wu Y-C. Historic perspectives on annonaceous acetogenins from the chemical bench to preclinical trials. Planta Med. 2010;76(13):1390-404.
93. Ahammadsahib KI, Hollingworth RM, McGovren JP, Hui YH, McLaughlin JL. Mode of action of bullatacin: A potent antitumor and pesticidal Annonaceous acetogenin. Life Sci. 1993;53(14):1113-20.
94. Holschneider CH, Johnson MT, Knox RM, Rezai A, Ryan WJ, Montz FJ. Bullatacin-In vivo and in vitro experience in an ovarian cancer model. Cancer Chemother Pharmacol. 1994;34 (2):166-70. (Pubitemid 24157982)
95. Chih H-W, Chiu H-F, Tang K-S, Chang F-R, Wu Y-C. Bullatacin, a potent antitumor annonaceous acetogenin, inhibits proliferation of human hepatocarcinoma cell line 2.2.15 by apoptosis induction. Life Sci. 2001;69(11):1321-31. (Pubitemid 32758701)
96. Oberlies NH, Croy VL, Harrison ML, McLaughlin JL. The Annonaceous acetogenin bullatacin is cytotoxic against multidrug-resistant human mammary adenocarcinoma cells. Cancer Lett. 1997;115(1):73-9. (Pubitemid 27144377)
97. Dong LF, Low P, Dyason JC, Wang XF, Prochazka L, Witting PK, et al. α-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene. 2008;27(31):4324-35. (Pubitemid 352010000)
98. Constantinou C, Papas A, Constantinou AI. Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. Int J Cancer. 2008;123(4):739-52. (Pubitemid 352032398)
99. Dong LF, Swettenham E, Eliasson J, Wang XF, Gold M, Medunic Y, et al. Vitamin E analogues inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: the role of oxidative stress. Cancer Res. 2007;67(24):11906-13.
100. Neuzil J, Weber T, Schr der A, Lu M, Ostermann G, Gellert N, et al. Induction of cancer cell apoptosis by α-tocopheryl succinate: molecular pathways and structural requirements. FASEB J. 2001;15(2):403-15. (Pubitemid 32141432)
101. Zhao Y, Neuzil J, Wu K. Vitamin E analogues as mitochondriatargeting compounds: from the bench to the bedside? Mol Nutr Food Res. 2009;53(1):129-39.
102. Brinkman MT, Karagas MR, Zens MS, Schned A, Reulen RC, Zeegers MP. Minerals and vitamins and the risk of bladder cancer: results from the New Hampshire Study. Cancer Causes Control. 2010;21(4):609-19.
103. Xiao D, Powolny AA, Singh SV. Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells. J Biol Chem. 2008;283(44):30151-63.
104. Lin JM, Amin S, Trushin N, Hecht SS. Effects of isothiocyanates on tumorigenesis by benzo[a]pyrene in murine tumor models. Cancer Lett. 1993;74(3):151-9. (Pubitemid 23346331)
105. Sugie S, Okumura A, Tanaka T, Mori H. Inhibitory effects of benzyl isothiocyanate and benzyl thiocyanate on diethylnitrosamine-induced hepatocarcinogenesis in rats. Jpn J Cancer Res. 1993;84(8):865-70. (Pubitemid 23262447)
106. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol. 2007;224(3):274-83. (Pubitemid 47575677)
107. Gledhill JR, Montgomery MG, Leslie AGW, Walker JE. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc Natl Acad Sci. USA. 2007;104 (34):13632-7. (Pubitemid 350003372)
108. Zheng J, Ramirez VD. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br J Pharmacol. 2000;130(5):1115-23. (Pubitemid 30453547)
109. Fulda S. Modulation of apoptosis by natural products for cancer therapy. Planta Med. 2010;76(11):1075-9.
110. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493-506. (Pubitemid 44136961)
111. Biasutto L, Mattarei A, Marotta E, Bradaschia A, Sassi N, Garbisa S, et al. Development of mitochondria-targeted derivatives of resveratrol. Bioorg Med Chem Lett. 2008;18(20):5594-7.
112. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010;70(22):9003-11.
113. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010;70 (19):7392-9.
114. Ko YH, Delannoy M, Hullihen J, Chiu W, Pedersen PL. Mitochondrial ATP synthasome: cristae-enriched membranes and a multiwell detergent screening assay yield dispersed single complexes containing the ATP synthase and carriers for Pi and ADP/ATP. J Biol Chem. 2003;278(14):12305-9. (Pubitemid 36800213)
115. Chen C, Ko Y, Delannoy M, Ludtke SJ, Chiu W, Pedersen PL. Mitochondrial ATP synthasome. J Biol Chem. 2004;279 (30):31761-8.
116. Dolce V, Scarcia P, Iacopetta D, Palmieri F. A fourth ADP/ATP carrier isoform in man: identification, bacterial expression, functional characterization and tissue distribution. FEBS Lett. 2005;579(3):633-7.
117. Chevrollier A, Loiseau D, Reynier P, Stepien G. Adenine nucleotide translocase 2 is a key mitochondrial protein in cancer metabolism. Biochim Biophys Acta Bioenerg. 2011;1807(6):562-7.
118. Jang JY, Choi Y, Jeon YK, Aung KCY, Kim CW. Overexpression of adenine nucleotide translocase 1 (ANT1) induces apoptosis and tumor regression in vivo. BMC Cancer. 2008;8.
119. Jang JY, Choi Y, Jeon YK, Kim CW. Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Canc Res. 2008;10(1).
120. Le Bras M, Borgne-Sanchez A, Touat Z, El Dein OS, Deniaud A, Maillier E, et al. Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res. 2006;66(18):9143-52. (Pubitemid 44521134)
121. Bauer MKA, Schubert A, Rocks O, Grimm S. Adenine nucleotide translocase-1, a component of the permeability transition pore, can dominantly induce apoptosis. J Cell Biol. 1999;147(7):1493-501. (Pubitemid 30027404)
122. Zamora M, Granell M, Mampel T, Viñas O. Adenine nucleotide translocase 3 (ANT3) overexpression induces apoptosis in cultured cells. FEBS Lett. 2004;563(1-3):155-60. (Pubitemid 38471591)
123. Gallerne C, Touat Z, Chen ZX, Martel C, Mayola E, Sharaf el dein O, et al. The fourth isoform of the adenine nucleotide translocator inhibits mitochondrial apoptosis in cancer cells. Int J Biochem Cell Biol. 2010;42(5):623-9.
124. Shoshan-Barmatz V, De Pinto V, Zweckstetter M, Raviv Z, Keinan N, Arbel N. VDAC, a multi-functional mitochondrial protein regulating cell life and death. Mol Aspects Med. 2010;31 (3):227-85.
125. De Pinto V, Guarino F, Guarnera A, Messina A, Reina S, Tomasello FM, et al. Characterization of human VDAC isoforms: a peculiar function for VDAC3? Biochim Biophys Acta Bioenerg. 2010;1797(6-7):1268-75.
126. Zaid H, Abu-Hamad S, Israelson A, Nathan I, Shoshan-Barmatz V. The voltage-dependent anion channel-1 modulates apoptotic cell death. Cell Death Differ. 2005;12(7):751-60. (Pubitemid 40945982)
127. Menzel VA, Cassará MC, Benz R, De Pinto V, Messina A, Cunsolo V, et al. Molecular and functional characterization of VDAC2 purified from mammal spermatozoa. Biosci Rep. 2009;29(6):351-62.
128. Liu B, Wang Z, Zhang W, Wang X. Expression and localization of voltage-dependent anion channels (VDAC) in human spermatozoa. Biochem Biophys Res Commun. 2009;378(3):366-70.
129. Simamura E, Shimada H, Ishigaki Y, Hatta T, Higashi N, Hirai KI. Bioreductive activation of quinone antitumor drugs by mitochondrial voltage-dependent anion channel 1. Anat Sci Int. 2008;83(4):261-6.
130. Baines CP, Kaiser RA, Sheiko T, Craigen WJ, Molkentin JD. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat Cell Biol. 2007;9 (5):550-5. (Pubitemid 46696536)
131. Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DP, et al. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature. 2004;427 (6973):461-5. (Pubitemid 38168501)
132. McEnery MW, Snowman AM, Trifiletti RR, Snyder SH. Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc Natl Acad Sci USA. 1992;89(8):3170-4.
133. Verrier F, Deniaud A, LeBras M, Métivier D, Kroemer G, Mignotte B, et al. Dynamic evolution of the adenine nucleotide translocase interactome during chemotherapy-induced apoptosis. Oncogene. 2004;23(49):8049-64. (Pubitemid 39531846)
134. Crompton M, Barksby E, Johnson N, Capano M. Mitochondrial intermembrane junctional complexes and their involvement in cell death. Biochimie. 2002;84(2-3):143-52.
135. Crompton M. Mitochondrial intermembrane junctional complexes and their role in cell death. J Physiol (Lond). 2000;529 (1):11-21.
136. Don AS, Kisker O, Dilda P, Donoghue N, Zhao X, Decollogne S, et al. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell. 2003;3(5):497-509. (Pubitemid 38340296)
137. Park D, Dilda PJ. Mitochondria as targets in angiogenesis inhibition. Mol Aspects Med. 2010;31(1):113-31.
138. Dilda PJ, Ramsay EE, Corti A, Pompella A, Hogg PJ. Metabolism of the tumor angiogenesis inhibitor 4-(N-(S-Glutathionylacetyl) amino)phenylarsonous acid. J Biol Chem. 2008;283 (51):35428-34.
139. Dilda PJ, Don AS, Tanabe KM, Higgins VJ, Allen JD, Dawes IW, et al. Mechanism of selectivity of an angiogenesis inhibitor from screening a genome-wide set of Saccharomyces cerevisiae deletion strains. J Natl Cancer Inst. 2005;97(20):1539-47. (Pubitemid 41631954)
140. Dilda PJ, Decollogne S, Weerakoon L, Norris MD, Haber M, Allen JD, et al. Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol. J Med Chem. 2009;52(20):6209-16.
141. Qin JZ, Xin H, Nickoloff BJ. 3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines. Biochem Biophys Res Commun. 2010;396(2):495-500.
142. Ihrlund LS, Hernlund E, Khan O, Shoshan MC. 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol. 2008;2 (1):94-101.
143. Liu XH, Zheng XF, Wang YL. Inhibitive effect of 3-bromopyruvic acid on human breast cancer MCF-7 cells involves cell cycle arrest and apoptotic induction. Chin Med J (Engl). 2009;122(14):1681-5.
144. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun. 2004;324(1):269-75. (Pubitemid 39311489)
145. Ganapathy-Kanniappan S, Geschwind JFH, Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I, et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res. 2009;29(12):4909-18.
146. Pereira da Silva AP, El-Bacha T, Kyaw N, dos Santos RS, Da- Silva WS, Almeida FCL, et al. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J. 2009;417(3):717-26.
147. Scatena R, Bottoni P, Pontoglio A, Mastrototaro L, Giardina B. Glycolytic enzyme inhibitors in cancer treatment. Expert Opin Investig Drugs. 2008;17(10):1533-45.
148. Meng F, Matteucci M, Har C. The antiproliferative activity of 3-Bromopyruvate is not due to selective inhibition of glycolysis. AACR Meeting Abstracts. 2008;2008:2714.
149. Ganapathy-Kanniappan S, Vali M, Kunjithapatham R, Buijs M, Syed LH, Rao PP, et al. 3-Bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Curr Pharm Biotechnol. 2010;11(5):510-7.
150. Flescher E. Jasmonates-a new family of anti-cancer agents. Anticancer Drugs. 2005;16(9):911-6. (Pubitemid 41416081)
151. Goldin N, Arzoine L,Heyfets A, Israelson A, Zaslavsky Z, Bravman T, et al. Methyl jasmonate binds to and detaches mitochondriabound hexokinase. Oncogene. 2008;27(34):4636-43.
152. Cohen S, Flescher E. Methyl jasmonate: a plant stress hormone as an anti-cancer drug. Phytochemistry. 2009;70(13-14):1600-9.
153. Fingrut O, Flescher E. Plant stress hormones suppress the proliferation and induce apoptosis in human cancer cells. Leukemia. 2002;16(4):608-16. (Pubitemid 34449741)
154. Reischer D, Heyfets A, Shimony S, Nordenberg J, Kashman Y, Flescher E. Effects of natural and novel synthetic jasmonates in experimental metastatic
155. Park C, Jin CY, Kim GY, Cheong J, Jung JH, Yoo YH, et al. A methyl jasmonate derivative, J-7, induces apoptosis in human hepatocarcinoma Hep3B cells in vitro. Toxicol Vitro. 2010;24 (7):1920-6.
156. Fulda S. Betulinic acid for cancer treatment and prevention. Int J Mol Sci. 2008;9(6):1096-107. (Pubitemid 351948841)
157. Fulda S, Scaffidi G, Susin SA, Krammer PH, Kroemer G, Peter ME, et al. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem. 1998;273(51):33942-8. (Pubitemid 29008858)
158. Fulda S, Susin SA, Kroemer G, Debatin KM. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res. 1998;58(19):4453-60. (Pubitemid 28450051)
159. Chiara F, Castellaro D, Marin O, Petronilli V, Brusilow WS, Juhaszova M, et al. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PloS one. 2008;3(3).
160. Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, Gambacorti-Passerini C, et al. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett. 2002;175(1):17-25. (Pubitemid 33153040)
161. Ren W, Qin L, Xu Y, Cheng N. Inhibition of betulinic acid to growth and angiogenesis of human colorectal cancer cell in nude mice. Chin Ger J Clin Oncol. 2010;9(3):153-7.
162. Shin YG, Cho KH, Chung SM, Graham J, Das Gupta TK, Pezzuto JM. Determination of betulinic acid in mouse blood, tumor and tissue homogenates by liquid chromatographyelectrospray mass spectrometry. J Chrom B Biomed Sci Appl. 1999;732(2):331-6. (Pubitemid 29460849)
163. Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/ pharmacodynamics of single-dose 3-O-(3′3′- dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus Infection. Antimicrob Agents Chemother. 2007;51(10):3574-81. (Pubitemid 47519346)
164. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Hideshima H, et al. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspasedependent and -independent apoptosis. Blood. 2005;106 (5):1794-800. (Pubitemid 41208596)
165. Fried LE, Arbiser JL. Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal. 2009;11(5):1139-48.
166. Chen F, Wang T, Wu YF, Gu Y, Xu XL, Zheng S, et al. Honokiol: a potent chemotherapy candidate for human colorectal carcinoma. World J Gastroenterol. 2004;10(23):3459-63. (Pubitemid 39549546)
167. Li Z, Liu Y, Zhao X, Pan X, Yin R, Huang C, et al. Honokiol, a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells. Eur J Obstet Gynecol Reprod Biol. 2008;140(1):95-102.
168. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature. 2008;455(7209):109-13.
169. Zheng X, Kan B, Gou M, Fu S, Zhang J, Men K, et al. Preparation of MPEG-PLA nanoparticle for honokiol delivery in vitro. Int J Pharm. 2010;386(1-2):262-7.
170. Floridi A, Paggi MG, Marcante ML. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst. 1981;66(3):497-9. (Pubitemid 11098551)
171. Belzacq AS, El Hamel C, Vieira HLA, Cohen I, Haouzi D, Métivier D, et al. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene. 2001;20(52):7579-87. (Pubitemid 33111858)
172. Ravagnan L, Marzo I, Costantini P, Susin SA, Zamzami N, Petit PX, et al. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene. 1999;18(16):2537-46. (Pubitemid 29216676)
173. Oudard S, Carpentier A, Banu E, Fauchon F, Celerier D, Poupon MF, et al. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol. 2003;63(1):81-6. (Pubitemid 36681647)
174. Notario B, Zamora M, Viñas O, Mampel T. All-trans-retinoic acid binds to and inhibits adenine nucleotide translocase and induces mitochondrial permeability transition. Mol Pharmacol. 2003;63(1):224-31. (Pubitemid 36043826)
175. Robert C, Delva L, Balitrand N, Nahajevszky S, Masszi T, Chomienne C, et al. Apoptosis induction by retinoids in eosinophilic leukemia cells: Implication of retinoic acid receptor-α signaling in all-trans-retinoic acid hypersensitivity. Cancer Res. 2006;66(12):6336-44.
176. Barna G, Sebestyén A, Weischede S, Peták I, Mihalik R, Formelli F, et al. Different ways to induce apoptosis by fenretinide and all-trans-retinoic acid in human B lymphoma cells. Anticancer Res. 2005;25(6 B):4179-85. (Pubitemid 41665202)
177. Marchetti P, Zamzami N, Joseph B, Schraen-Maschke S, Méreau- Richard C, Costantini P, et al. The novel retinoid 6-[3-(1-adamantyl)-4- hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res. 1999;59(24):6257-66. (Pubitemid 30035651)
178. Lotan R. Retinoids in cancer chemoprevention. FASEB J. 1996;10(9):1031-9. (Pubitemid 26285979)
179. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99(3):759-67. (Pubitemid 34525534)
180. Milligan DW, Wheatley K, Littlewood T, Craig JI, Burnett AK, Group NHOCS. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood. 2006;107 (12):4614-22. (Pubitemid 43882605)
181. Burnett AK, Hills RK, Green C, Jenkinson S, Koo K, Patel Y, et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood. 2010;115(5):948-56.
182. Dilda PJ, Hogg PJ. Arsenical-based cancer drugs. Cancer Treat Rev. 2007;33(6):542-64. (Pubitemid 47355338)
183. Dang CV. Glutaminolysis: supplying carbon or nitrogen or both for cancer cells? Cell Cycle. 2010;9(19):3884-6.
184. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 2007;104(49):19345-50.
185. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35(8):427-33.
186. Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Mates JM, et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci USA. 2011 May 24;108(21):8674-9.
187. Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009 Oct 15;69(20):7986-93.
188. Meng M, Chen S, Lao T, Liang D, Sang N. Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells. Cell Cycle. 2010;9(19):3921-32.
189. Qin JZ, Xin H, Nickoloff BJ. Targeting glutamine metabolism sensitizes melanoma cells to TRAIL-induced death. Biochem Biophys Res Commun. 2010;398(1):146-52.
190. Thornburg J, Nelson K, Clem B, Lane A, Arumugam S, Simmons A, et al. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res. 2008;10(5):R84.
191. Mohanti BK, Rath GK, Anantha N, Kannan V, Das BS, Chandramouli BAR, et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: Phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys. 1996;35 (1):103-11. (Pubitemid 26137174)
192. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100(13):4298-302. (Pubitemid 36001941)
193. Arrieta O, González-De la Rosa CH, Aréchaga-Ocampo E, Villanueva-Rodríguez G, Cerón-Lizárraga TL, Martínez-Barrera L, et al. Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(21):3463-71.
194. Kumaran G, Middleton MR, Zee YK, McGuigan L, Clamp AR, Hogg PJ, et al. Selective inhibition of proliferating endothelial cells: a phase I study of the novel organoarsenical compound GSAO in patients with advanced solid tumors. ASCO Meeting Abstracts. 2010;28(15 Suppl): TPS167.
195. Maroun JA, Maksymiuk A, Eisenhauer E. Phase II study of acivicin in non-small cell lung cancer: a National Cancer Institute of Canada study. Cancer Treat Rep. 1986;70 (11):1327-8. (Pubitemid 17184299)
196. Maroun JA, Fields AL, Pater JL. Phase II study of acivicin in colorectal carcinoma: a National Cancer Institute of Canada study. Cancer Treat Rep. 1984;68(9):1121-3. (Pubitemid 14027406)
197. Bonomi P, Finkelstein D, Chang A. Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer: an Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1994;17(3):215-7. (Pubitemid 24160610)
198. Maroun JA, Stewart DJ, Verma S, Evans WK, Eisenhauer E. Phase I study of acivicin and cisplatin in non-small-cell lung cancer: a National Cancer Institute of Canada study. Am J Clin Oncol. 1990;13(5):401-4. (Pubitemid 20344515)
199. Adolphson CC, Ajani JA, Stroehlein JR. Phase II trial of acivicin in patients with advanced colorectal carcinoma. Am J Clin Oncol. 1986;9(3):189-91. (Pubitemid 16038526)